^
Association details:
| Biomarker: | FGFR2 mutation |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | zoligratinib (Debio 1347) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
Published date:
04/29/2021
Excerpt:
...we identified FGFR2 extracellular domain in-frame deletions (EID) in 5 of 178 (2.8%) patients with IHCC, including two patients with FGFR2 p.H167_N173del. Expression of this FGFR2 EID in NIH3T3 cells resulted in constitutive FGFR2 activation, oncogenic transformation, and sensitivity to FGFR inhibitors. Three patients with FGFR2 EIDs were treated with Debio 1347, an oral FGFR1/2/3 inhibitor, and all showed partial responses...
